ROBERT APPELGATE, M.D.; DOUGLAS SCHWARTZ, M.D.; WILLIAM M. BENNETT, M.D.
To the editor: Plasma exchange therapy has achieved widespread acceptance as a therapeutic modality in a number of serious illnessses such as Goodpasture's syndrome, rapidly progressive glomerulonephritis, and thrombotic thrombocytopenic purpura (1). A recent report has emphasized the frequent life-threatening bacterial infections that may complicate this form of therapy (2). We recently studied tobramycin concentrations during plasma exchange treatments for thrombotic thrombocytopenic purpura. Dosage supplementation is needed to maintain therapeutic plasma concentrations.
A 63-year-old woman had a 6-month history of progressive muscle tenderness and weakness. Muscle biopsy showed inflammatory myositis with perivascular lymphocytic infiltration. Hematocrit, hemoglobin, urinalysis, and renal function
APPELGATE R, SCHWARTZ D, BENNETT WM. Removal of Tobramycin During Plasma Exchange Therapy. Ann Intern Med. ;94:820–821. doi: 10.7326/0003-4819-94-6-820_2
Download citation file:
Published: Ann Intern Med. 1981;94(6):820-821.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use